The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards ROR? and ROR?T.

ABSTRACT: The RORC (RAR related orphan receptor C) gene produces two isoforms by alternative promoter usage: ROR? (nuclear receptor ROR-gamma isoform 1) and ROR?T (nuclear receptor ROR-gamma isoform 1). Both proteins have distinct tissue distributions and are involved in several physiological processes, including glucose/lipid metabolism and the development of Th17 lymphocytes. Previously, we developed a stably transfected reporter cell line and used it to screen a library of kinase inhibitors. We found that AZ5104 acts as an ROR? agonist at low micromolar concentrations. Molecular docking analysis showed that this compound occupies the ligand binding domain of the receptor with a significant docking score. However, analysis of the biological activity of this compound in Th17 cells revealed that it downregulates ROR?T expression and Th17-related cytokine production via inhibition of SRC-ERK-STAT3 (SRC proto-oncogene - extracellular regulated MAP kinase - signal transducer and activator of transcription 3). We thus identified a compound acting as an agonist of ROR? that, due to the inhibition of downstream elements of EGFR (epidermal growth factor receptor) signaling, exerts different biological activity towards a Th17-specific isoform. Additionally, our results may be relevant in the future for the design of treatments targeting signaling pathways that inhibit Th17-related inflammation in certain autoimmune disorders.

SUBMITTER: Karas K 

PROVIDER: S-EPMC6887705 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature